BEIJING, China, July 6, 2026
InnoCare Pharma has announced a significant milestone in its oncology pipeline with the first patient dosed in the clinical trial of ICP-B208, a novel CDH17-targeted antibody-drug conjugate (ADC) developed for the treatment of multiple gastrointestinal cancers. The investigational therapy, created using InnoCare’s proprietary ADC platform, combines a humanized anti-CDH17 monoclonal antibody with a potent in-house developed cytotoxic payload connected through a protease-cleavable linker, enabling highly targeted tumor cell destruction while improving stability and safety. The advancement marks another important step in InnoCare’s strategy to expand its portfolio of next-generation precision oncology therapies. As no CDH17-targeted ADC has yet received global regulatory approval, ICP-B208 has the potential to become a first-in-class targeted treatment for patients with difficult-to-treat gastrointestinal malignancies, an area that continues to represent a major unmet medical need worldwide.
Novel CDH17-Targeted ADC Designed for Precision Cancer Therapy
ICP-B208 targets Cadherin-17 (CDH17), a calcium-dependent cell adhesion protein that is highly expressed in several gastrointestinal cancers and plays a critical role in tumor growth, invasion, migration, and metastasis. Because CDH17 expression is largely restricted to tumor tissues while remaining limited in healthy organs, it has emerged as an attractive target for precision antibody-drug conjugate therapy. Built on InnoCare’s proprietary ADC technology platform, ICP-B208 delivers a highly potent cytotoxic payload directly into cancer cells after binding to CDH17, maximizing tumor-killing activity while reducing exposure to normal tissues.
The investigational therapy is being developed for a range of gastrointestinal malignancies, including colorectal cancer, gastric cancer, pancreatic ductal adenocarcinoma, and biliary tract cancer. With no approved CDH17-targeted ADCs currently available anywhere in the world, successful clinical development could establish a completely new therapeutic option for patients with advanced gastrointestinal cancers.
Clinical Trial Expands InnoCare’s Growing ADC Pipeline
Advertisement
The dosing of the first patient represents an important milestone for InnoCare’s expanding antibody-drug conjugate portfolio, following continued progress of its B7-H3-targeted ADC, ICP-B794. The company has invested heavily in developing an integrated ADC discovery platform capable of generating innovative oncology candidates with enhanced efficacy, optimized stability, and improved safety profiles. By combining highly selective monoclonal antibodies with proprietary linker and payload technologies, InnoCare aims to create next-generation targeted therapies capable of delivering more effective treatment while minimizing systemic toxicity.
The initiation of clinical evaluation for ICP-B208 demonstrates the company’s continued commitment to advancing precision oncology, addressing cancers with significant unmet medical needs through innovative targeted therapeutics. The ongoing study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of ICP-B208 in patients with advanced gastrointestinal cancers.
Advancing Global Innovation in Antibody-Drug Conjugates
The initiation of clinical development for ICP-B208 further strengthens InnoCare Pharma’s position as an emerging innovator in the rapidly expanding antibody-drug conjugate market, one of the fastest-growing segments in oncology drug development. The company currently maintains a robust pipeline that includes three approved medicines, more than ten clinical-stage investigational therapies, and multiple additional preclinical programs targeting cancer and autoimmune diseases.
As global interest in ADC technologies continues to accelerate, novel targets such as CDH17 offer significant opportunities to improve outcomes for patients whose cancers have limited treatment options. The first patient dosed in the ICP-B208 clinical trial marks an important milestone toward evaluating the therapy’s clinical potential and supports InnoCare’s long-term strategy of delivering first-in-class and best-in-class precision medicines for patients worldwide while expanding its leadership in targeted cancer therapeutics.
Source: InnoCare Pharma press release
